Nini Wu, MD, MBA, Chief Medical & Development Officer, Navista

home / authors / nini-wu

Articles

The Growing Financial Burden on Patients and Caregivers in Cancer Care

The Growing Financial Burden on Patients and Caregivers in Cancer Care

Nini Wu, MD, MBA, Chief Medical & Development Officer, Navista
April 24th 2025

Challenges Facing Clinicians and Community Oncology Practices

Challenges Facing Clinicians and Community Oncology Practices

Nini Wu, MD, MBA, Chief Medical & Development Officer, Navista
April 23rd 2025
The Promise of Pragmatic Innovation in Community Oncology

The Promise of Pragmatic Innovation in Community Oncology

Nini Wu, MD, MBA, Chief Medical & Development Officer, Navista
May 21st 2024

Nini Wu, MD, MBA, highlights practical technology in community oncology and how it is used to enhance patient and staff experiences.

Unlocking the Potential of Technology in Community Oncology

Unlocking the Potential of Technology in Community Oncology

Jordyn Sava;Nini Wu, MD, MBA, Chief Medical & Development Officer, Navista
May 15th 2024

In this episode of Targeted Talks, Nini Wu, MD, MBA, shares her insights on the ever-changing world of technology in community oncology.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Challenges Facing Clinicians and Community Oncology Practices
Published: April 23rd 2025 | Updated: April 27th 2025
Challenges Facing Clinicians and Community Oncology Practices
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease
Published: April 15th 2025 | Updated: April 27th 2025
Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease
FDA Clears Phase 1 Study of TGW101 for Advanced Solid Tumor Treatment
Published: April 24th 2025 | Updated: April 27th 2025
FDA Clears Phase 1 Study of TGW101 for Advanced Solid Tumor Treatment
FDA Grants Priority Review to Avutometinib/Defactinib Combo in KRAS+ Ovarian Cancer
Published: January 2nd 2025 | Updated: April 27th 2025
FDA Grants Priority Review to Avutometinib/Defactinib Combo in KRAS+ Ovarian Cancer